Teva and Immunai partner to improve clinical decision making
The companies will focus on mechanisms of action, dose selection and biomarker analyses
Read Moreby Emily Kimber | Nov 18, 2024 | News | 0
The companies will focus on mechanisms of action, dose selection and biomarker analyses
Read Moreby Jen Brogan | May 13, 2024 | News | 0
The funding will help to support research across epigenetics, immunology and cell signalling
Read Moreby Jen Brogan | Dec 19, 2023 | News | 0
In 2020, there were over ten million deaths worldwide associated with cancer
Read Moreby Lucy Parsons | Dec 3, 2020 | News | 0
Partnership will seek to develop small molecules for oncology/immunology targets
Read Moreby Selina McKee | Jul 21, 2017 | News | 0
Sanofi has signed a research pact and licensing deal with Ablynx that could bring as much as $2.7 billion euros to the Belgian biotech’s coffers if all targets are met.
Read More





PharmaTimes Media Ltd.
44 Maiden Lane
Covent Garden
London
WC2E 7LN
E: editorial@pharmatimes.com
E: subscriptions@pharmatimes.com
T: +44 (0)20 7240 6999
